Guohong Hu

Nanchang, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.

Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial.

Journal: The British journal of dermatology

Published: August 25, 2025

Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis.

Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: July 25, 2025

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial.

Journal: The British journal of dermatology

Published: July 02, 2025

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Journal: The British journal of dermatology

Published: July 02, 2025

Upadacitinib Coadministered with Methylprednisolone for Effective Treatment of SJS/TEN Overlap Syndrome: A Case Report.

Upadacitinib Coadministered with Methylprednisolone for Effective Treatment of SJS/TEN Overlap Syndrome: A Case Report.

Journal: Clinical, cosmetic and investigational dermatology

Published: June 06, 2025

Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial.

Safety and efficacy of stapokibart, an anti-interleukin-4 receptor α monoclonal antibody, in children aged 6-11 years with moderate-to-severe atopic dermatitis: an open-label single-arm phase Ib/IIa trial.

Journal: The British journal of dermatology

Published: April 29, 2025

Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.

Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.

Journal: Journal of the American Academy of Dermatology

Published: April 28, 2025

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial.

Journal: Dermatology and therapy

Published: December 05, 2024

Gallic Acid Ameliorates Atopic Dermatitis-Like Skin Inflammation Through Immune Regulation in a Mouse Model.

Gallic Acid Ameliorates Atopic Dermatitis-Like Skin Inflammation Through Immune Regulation in a Mouse Model.

Journal: Clinical, cosmetic and investigational dermatology

Published: August 02, 2021

Occludin is a target of Src kinase and promotes lipid secretion by binding to BTN1a1 and XOR.

Occludin is a target of Src kinase and promotes lipid secretion by binding to BTN1a1 and XOR.

Journal: PLoS biology

Published: May 07, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026